Lab-Grown Mini Kidneys Are Bringing Science Closer to Custom Organs

Lab-Grown Mini Kidneys Are Bringing Science Closer to Custom Organs

A model of a human kidney.

(Photo by Robina Weermeijer on Unsplash)


Keep ReadingKeep Reading
Ron Shinkman
Ron Shinkman is a veteran journalist whose work has appeared in the New England Journal of Medicine publication Catalyst, California Health Report, Fierce Healthcare, and many other publications. He has been a finalist for the prestigious NIHCM Foundation print journalism award twice in the past five years. Shinkman also served as Los Angeles Bureau Chief for Modern Healthcare and as a staff reporter for the Los Angeles Business Journal. He has an M.A. in English from California State University and a B.A. in English from UCLA.
Roald Dahl lost a child to measles. Here's what he has to say about the new outbreaks.

Olivia Dahl, shortly before her death from measles in 1962.

In 1962, the world was a remarkably different place: Neil Armstrong had yet to take his first steps on the lunar surface, John F. Kennedy was serving as president of the United States, and the Beatles were still a few years away from superstardom, having just recorded their first single.

The word “measles” was also a household name. Measles, which still exists in parts of the world today, is a highly contagious viral infection that typically causes fever, cough, muscle pain, fatigue, and a distinctive red rash. Measles was so pervasive around the world in 1962 that most children had gotten sick with it before the age of fifteen—but even though it was common, it was far from harmless. Measles killed around 400 to 500 people per year in the United States, and approximately 2.6 million people each year worldwide. Countless others suffered severe complications from measles, such as permanent blindness.

Keep ReadingKeep Reading
Sarah Watts

Sarah Watts is a health and science writer based in Chicago.

natural killer cell
NIAID, CC BY 2.0 <https://creativecommons.org/licenses/by/2.0>, via Wikimedia Commons

On today’s episode of Making Sense of Science, I’m honored to be joined by Dr. Paul Song, a physician, oncologist, progressive activist and biotech chief medical officer. Through his company, NKGen Biotech, Dr. Song is leveraging the power of patients’ own immune systems by supercharging the body’s natural killer cells to make new treatments for Alzheimer’s and cancer.

Whereas other treatments for Alzheimer’s focus directly on reducing the build-up of proteins in the brain such as amyloid and tau in patients will mild cognitive impairment, NKGen is seeking to help patients that much of the rest of the medical community has written off as hopeless cases, those with late stage Alzheimer’s. And in small studies, NKGen has shown remarkable results, even improvement in the symptoms of people with these very progressed forms of Alzheimer’s, above and beyond slowing down the disease.

Keep ReadingKeep Reading
Matt Fuchs
Matt Fuchs is the host of the Making Sense of Science podcast and served previously as the editor-in-chief of Leaps.org. He writes as a contributor to the Washington Post, and his articles have also appeared in the New York Times, WIRED, Nautilus Magazine, Fortune Magazine and TIME Magazine. Follow him @fuchswriter.